Back to discover
Disease
Colon carcinoma
Late-stage therapeutic development
Also known as carcinoma of colon, carcinoma of the colon, colonic carcinoma, colon cancer.
19
Clinical trials
12
Associated genes
4
Related proteins
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Market withdrawal: Lextemy (EMA)
Regulatory2021-06-21EMA
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 5 clinical trials expected to report results, the earliest in Q4 2026.
- 12 industry developments reported.
Upcoming Milestones
- Q4 2026A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy Delivery
- Q1 2028A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy
- Q4 2028A Phase II Clinical Trial of Neoadjuvant Zanidatamab for HER2+ Localized Colorectal Cancer
- Q1 2032Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)
- Q2 2034Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer
Major developments
Upcoming trial readoutHigh impact
Results expected Q2 20342026-07-02
Major trial resultsImportant
Results posted2026-02-10
Clinical MilestonesViewHide
Results posted
Results expected
- 2026-07-02Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon CancerResults expected Q2 2034
- 2026-04-17A Phase II Clinical Trial of Neoadjuvant Zanidatamab for HER2+ Localized Colorectal CancerResults expected Q4 2028
- 2026-03-05Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)Results expected Q1 2032
- 2026-01-06A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy DeliveryResults expected Q4 2026
- 2025-12-05A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral NeuropathyResults expected Q1 2028
Other updates
Industry & MarketView all 12Hide
- 2026-10-09FDA Approves Atezolizumab With Chemo Combo for Colon CancerRegulatory news · Medscape Medical News
- 2026-10-08FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancerRegulatory news · FDA Drug Approvals
- 2026-10-09Roche’s Tecentriq snags FDA label expansion in type of colon cancerManufacturing · Pharmaceutical Technology
- 2026-07-13Agenus scraps phase 3 colorectal study after 3 months to narrow focus to colon cancerTrial news · Fierce Biotech
- 2026-10-29Intensified Adjuvant Chemo No Better Than Standard in High-Risk Colon CancerIndustry · MedPage Today — Hematology/Oncology
+7 more in the activity timeline below
Activity timeline19
- 2026-10-29IndustryIntensified Adjuvant Chemo No Better Than Standard in High-Risk Colon CancerIndustry · MedPage Today — Hematology/Oncology
- 2026-10-09IndustryFDA Approves Atezolizumab With Chemo Combo for Colon CancerRegulatory news · Medscape Medical News
- 2026-10-09IndustryRoche’s Tecentriq snags FDA label expansion in type of colon cancerManufacturing · Pharmaceutical Technology
- 2026-10-08IndustryFDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancerRegulatory news · FDA Drug Approvals
- 2026-10-08IndustryAccelerated Aging and Colon Cancer; Hepatitis B From a Cat? Food Triggers in IBDIndustry · MedPage Today — Gastroenterology
- 2026-09-17IndustryPamela Anderson's Hepatitis; Statins After Colon Cancer; Fall Vaccines in Gastro/HepIndustry · MedPage Today — Gastroenterology
- 2026-07-30IndustryHow one amino acid might help fight colon cancer and infectionsIndustry · Science News
- 2026-07-16IndustryScientists finally solved how a common gut bacterium triggers colon cancerIndustry · Science Daily
- 2026-07-13IndustryAgenus scraps phase 3 colorectal study after 3 months to narrow focus to colon cancerTrial news · Fierce Biotech
- 2026-07-02ClinicalRandomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon CancerResults expected Q2 2034
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approved & established therapies
Bevacizumabapproved
Product authorisation ended — Treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer,… (2021)
Clinical trials
The current development programme across all trial phases.
Clinical programme
19
6
1
6
Recruiting
Recently completed
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
Product approvals and authorisations
2020emaBiosimilar approval — Bevacizumab· Aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1 of the SmPC. Aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Aybintio in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1 of the SmPC. Aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1 of the SmPC). Aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1 of the SmPC). Aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. Aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents (see section 5.1 of the SmPC). Aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1 of the SmPC). source ↗
2018emaBiosimilar approval — Bevacizumab· Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. Mvasi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. Mvasi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. Mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. Mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. source ↗
Other regulatory activity
2021emaProduct authorisation ended — Bevacizumab· Treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix. source ↗
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Synonyms
carcinoma of colon, carcinoma of the colon, colonic carcinoma, colon cancer
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.